Oxidative stress biomarkers in Fabry disease: is there a room for them?
Open Access
- 27 July 2020
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 267 (12) , 3741-3752
Abstract
Background: Fabry disease (FD) is an X-linked lysosomal storage disorder, caused by deficient activity of the alpha-galactosidase A enzyme leading to progressive and multisystemic accumulation of globotriaosylceramide. Recent data point toward oxidative stress signalling which could play an important role in both pathophysiology and disease progression.Methods: We have examined oxidative stress biomarkers [Advanced Oxidation Protein Products (AOPP), Ferric Reducing Antioxidant Power (FRAP), thiolic groups] in blood samples from 60 patients and 77 healthy controls.Results: AOPP levels were higher in patients than in controls (p < 0.00001) and patients presented decreased levels of antioxidant defences (FRAP and thiols) with respect to controls (p < 0.00001). In a small group of eight treatment-naïve subjects with FD-related mutations, we found altered levels of oxidative stress parameters and incipient signs of organ damage despite normal lyso-Gb3 levels.Conclusions: Oxidative stress occurs in FD in both treated and naïve patients, highlighting the need of further research in oxidative stress-targeted therapies. Furthermore, we found that oxidative stress biomarkers may represent early markers of disease in treatment-naïve patients with a potential role in helping interpretation of FD-related mutations and time to treatment decision.Keywords
Funding Information
- Partially supported by an Investigator-Initiated Research grant from Shire International GmbH, a Takeda company. (IIR-ITA-001466)
This publication has 31 references indexed in Scilit:
- Early initiation of enzyme replacement therapy in classical Fabry disease normalizes biomarkers in clinically asymptomatic pediatric patientsMolecular Genetics and Metabolism Reports, 2019
- Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patientsClinical Genetics, 2019
- The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: Data from individual patients and family studiesMolecular Genetics and Metabolism, 2015
- Evaluation of oxidative stress markers and cardiovascular risk factors in Fabry Disease patientsGenetics and Molecular Biology, 2012
- New mutations in the GLA gene in Brazilian families with Fabry diseaseJournal of Human Genetics, 2012
- Fabry disease: Characterization of ?-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency alleleHuman Mutation, 2003
- Fabry disease: D313Y is an α-galactosidase A sequence variant that causes pseudodeficient activity in plasmaMolecular Genetics and Metabolism, 2003
- Regional Cerebral Hyperperfusion and Nitric Oxide Pathway Dysregulation in Fabry DiseaseCirculation, 2001
- Advanced Oxidation Protein Products as Novel Mediators of Inflammation and Monocyte Activation in Chronic Renal Failure,The Journal of Immunology, 1998
- The Ferric Reducing Ability of Plasma (FRAP) as a Measure of “Antioxidant Power”: The FRAP AssayAnalytical Biochemistry, 1996